ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Los Angeles, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Los Angeles, CA, USA:

RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma.The drugs invo...

Active, not recruiting
Follicular Lymphoma
Drug: Rituximab
Drug: PF04518600

Phase 1

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Duarte, California, United States and 5 other locations

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling
Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Duarte, California, United States and 6 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Los Angeles, California, United States and 89 other locations

DS-3201b is an experimental drug that is being investigated in clinical research.Adults with non-Hodgkin lymphoma (NHL) may be able to join ...

Active, not recruiting
Lymphoma, Malignant
Non-hodgkin Lymphoma
Drug: DS-3201b

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Duarte, California, United States and 20 other locations

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: HMPL-523

Phase 1

HUTCHMED
HUTCHMED

Downey, California, United States and 31 other locations

and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...

Active, not recruiting
B Cell Lymphoma
Mantle Cell Lymphoma
Drug: Ibrutinib
Drug: Palbociclib

Phase 2

Alliance Foundation Trials

Duarte, California, United States and 8 other locations

Locations recently updated

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Los Angeles, California, United States and 66 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Downey, California, United States and 31 other locations

1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for whic...

Enrolling
Lymphoma
Solid Tumor, Adult
Drug: Fadraciclib

Phase 1, Phase 2

Cyclacel Pharmaceuticals

Duarte, California, United States and 3 other locations

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

Enrolling
T-cell Lymphoma
Cutaneous T-cell Lymphoma
Drug: Fenretinide

Phase 1

SciTech Development

Los Angeles, California, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems